Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annual PAINWeek National Conference, taking place September 6-9, 2022 in Las Vegas, NV. “Collegium is excited to support 11 posters regarding our meaningfully differentiated product portfolio that will be presented at PAINWe
Last week, Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright has downgraded the stock to Neutral with no price target vs. prior Buy with a $29 target. "We applaud the recent financial results but have been disappointed by Xtampza and Belbuca Rx trends, which are below our projections, down slightly Y/Y, and trajectories currently flat at best," the analyst writes. The analyst believes that